Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Fidelity National Information Servcs Inc (FIS) vs Pfizer Inc (PFE) Price & Performance

Fidelity National Information Servcs IncTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Fidelity National Information Servcs Inc vs Pfizer Inc — how do they compare? Fidelity National Information Servcs Inc trades at $42.9 (market cap $21.92B), while Pfizer Inc trades at $26.6 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 7× Fidelity National Information Servcs Inc's market cap, and Pfizer Inc pays the higher dividend (6.36%). Which is the better fit depends on your goals.

FISPFE
Market Cap
$21.92B$154.18B
Sector
TechnologyHealth
52-Week High
$72.77$28.56
52-Week Low
$37.72$23.60
Enterprise Value
$42.43B$205.67B
Dividend Yield
4.14%6.36%
Volume
29,869,932

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Fidelity National Information Servcs Inc

FIS trades at $42.77, down slightly on the day, with a bearish technical signal. The company reported Q2 2026 earnings of $1.48 per share, beating estimates, driven by Banking Solutions growth. Recent news highlights the global expansion of its Digital One Commercial platform into the APAC region. Valuation metrics appear attractive with a P/E of 6.57 and a consensus price target of $50.20, though the company lowered its full-year Capital Markets outlook.

The outlook is mixed; strong fundamentals and analyst support suggest upside potential, but near-term price action is weak and execution risks in the Capital Markets segment pose a challenge. The stock offers value but requires monitoring of the revised guidance and competitive pressures in the fintech space.

Pfizer Inc

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Fidelity National Information Servcs Inc

Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.

Read more on FIS

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE